Relay Therapeutics Insider Sale Tops $3 Million as Stock Surges 500% in Past Year
Relay Therapeutics (NASDAQ:RLAY) Chief Financial Officer Thomas Catinazzo exercised stock options and sold 187,163 shares of common stock on June 22, 2026, according to a filing with the Securities and Exchange Commission. The transaction, valued at more than $3 million, was conducted under a Rule 10b5-1 trading plan adopted in October 2025.
Following the sale, Catinazzo still holds more than 223,000 stock options, keeping him meaningfully exposed to the company's future performance. Option exercises and subsequent sales are routine among biotech executives, often tied to tax planning or diversification rather than a bearish view on the stock.
The bigger story for Relay remains its clinical pipeline and the staggering run-up in its share price — up roughly 500% over the past 12 months. In May, the company reported promising early Phase 2 data for zovegalisib in patients with PIK3CA-driven vascular anomalies. The readout showed a 60% volumetric response rate at 12 weeks, with 89% of investigators and 79% of patients reporting clinical improvement. Management said the results reinforce its belief that zovegalisib could “meaningfully change the treatment paradigm” for these patients, and expansion cohorts are already under way.
Relay also strengthened its balance sheet last month by pricing a public offering expected to raise about $275 million before expenses, providing additional capital to fund late-stage clinical development and pipeline expansion. For long-term investors, the focus should remain on clinical execution rather than insider activity. Relay's ultimate value will hinge on whether its precision medicine platform can convert promising trial data into regulatory approvals and commercial success.
Before you buy stock in Relay Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Relay Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $398,052!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,181,688!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 29, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year was originally published by The Motley Fool